Terminated PHASE2 INTERVENTIONAL 1-arm NCT03858972

Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC (CONTESSA 2)

Multinational, Multicenter, Phase 2 Study of Tesetaxel Plus a Reduced Dose of Capecitabine in Patients With HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane

Sponsor: Odonate Therapeutics, Inc.

Conditions Breast Cancer

Interventions Capecitabine Tesetaxel

Updated 9 times since 2019 Last updated: Jul 26, 2021 Started: Feb 5, 2019 Primary completion: Jun 11, 2021 Completion: Jun 11, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The Sponsor has discontinued the development of tesetaxel

Other terminated trials from Odonate Therapeutics, Inc.

More terminations from Odonate Therapeutics, Inc.

Other Breast Cancer trials with similar outcome

Browse all Breast Cancer trials

This PHASE2 trial investigates Breast Cancer and is currently terminated or withdrawn. Odonate Therapeutics, Inc. leads this study, which shows 9 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Sep 2021 — Jul 2024 [monthly]

Terminated PHASE2

Status: Active Not Recruiting → Terminated
Feb 2021 — Sep 2021 [monthly]

Active Not Recruiting PHASE2

▶ Show 4 earlier versions

Jan 2021 — Feb 2021 [monthly]

Active Not Recruiting PHASE2
Nov 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Nov 2019 — Nov 2020 [monthly]

Recruiting PHASE2
Apr 2019 — Nov 2019 [monthly]

Recruiting PHASE2

First recorded

Feb 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Odonate Therapeutics, Inc.

Data source: Odonate Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Albury, Australia , Boston, United States , Daegu, South Korea , Dallas, United States , East Setauket, United States , Fort Myers, United States , Germantown, United States , Goyang, South Korea , Lakewood, United States and 10 more locations